Phraxis

The number of patients requiring hemodialysis is expected to reach 774,000 with an annual incidence of more than 160,000 new patients per year who require vascular access for hemodialysis. Vascular access for hemodialysis is creating a special pathway in the body to cleanse the blood when the kidneys aren’t working (End Stage Renal Disease). Two methods of permanent vascular access: Arteriovenous Fistula (AVF) Arteriovenous Grafts (AVG) Phraxis, Inc is a Minneapolis MN based company that has developed the EndoForce™ Venous Anastomotic Connector to provide a procedural technique for AVG implantation that may lessen the neointimal hyperplasia-induced stenosis that is associated with conventional sutured venous anastomosis. See our complete clinical study of the EndoForce™ Venous Endovascular Anastomotic Connector here: https://pubmed.ncbi.nlm.nih.gov/36895157/ And join the movement at www.phraxis.com as we seek FDA approval. The EndoForce™ Venous Anastomotic Connector is an investigational device. Limited by Federal (United States) law to investigational use.